VANCOUVER, BC / ACCESSWIRE / April 10, 2017
Abattis Bioceuticals Corp. (CSE:ATT) (ATTBF) (the “Company” or “Abattis”) is pleased to announce the appointment of Robert Abenante as President and Chief Executive Officer of the Company.
Mr. Abenante is a seasoned executive with extensive public company experience. Mr. Abenante is a Chartered Professional Accountant (CPA, CA) who also holds a Masters. After his tenures with PricewaterhouseCoopers and Deloitte, Mr. Abenante founded and/or served as an officer/director of several public and private companies across various industries, ranging from energy and mining to agriculture technology and nutraceuticals.
“We are very excited to bring aboard someone with Mr. Abenante’s high caliber skillset and impressive experience to lead our Company,” states Rene David, the Company’s CFO and Director. “His reputation for efficiently building management teams, cleaning up corporate structures and raising capital will drive growth in our Company both organically and through joint ventures, mergers and acquisitions.”
After an extensive search, Abattis selected Mr. Abenante to lead the Company as its President and CEO. The timing is critical, as the Company is targeting to launch its first lab in Langley, BC this month. The Company’s subsidiary, Northern Vine Canada Inc. (“Northern Vine”), holds a controlled substances testing license issued by Health Canada. Northern Vine obtained the license after fulfilling Health Canada’s rigorous specifications and successfully passing all its thorough inspections. Once the lab is opened, the Company will legally be able to test dried plant products, extracts, derivatives and edibles for licensed producers and patients under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) regulatory framework. Although independent cannabis testing and analytical services are currently being used by some Licensed Producers under the ACMPR, the recently released “Report of the Task Force on Cannabis Legalization and Regulation” emphasized the importance of independent lab testing of all cannabis products. For more information about Northern Vine, see the Company website and below.
Mr. Abenante states, “I am very happy to be joining the Company, which is on the verge of attaining significant milestones in a rapidly evolving industry. Our focus in the short-term will be on opening our first lab and immediately beginning to grow our client base. We also have many late-stage products in our pipeline, ranging from CBD oils to Hemp drinks. Health sciences and nutraceuticals have long been a passion of mine, therefore, in addition to launching our lab and bringing late stage products to the market, I also intend to work with our talented professionals and scientists to reinvigorate our formulation and testing program so the Company can continue to bring innovative and cutting-edge products to the market through our Vergence division. It is my mission to raise the Company to the top of our industry through aggressive growth, both organically and through acquisitions, and my vision is to make significant positive contributions to the medical community through our research and development.”
The Company’s management and its Board of Directors are confident that Mr. Abenante’s ability and experience will help add organizational structure to the team and unite it around a clear vision to achieve its ambitious growth targets. “We are all excited to rally around Mr. Abenante’s vision and strategy to lead Abattis into becoming one of the premier companies in the cannabis sector,” says Jim Irvine, a director of the Company.
About Abattis Bioceuticals Corp.
Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.
About Northern Vine Canada Inc.
Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian cannabis market.
About Vergence Visionary Bioceuticals Corp.
Vergence Visionary Bioceuticals, dba Vergence Sales and Marketing Group, is a wholly owned subsidiary of Abattis, based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast-growing market for natural, safe and effective natural products that meet unmet wellness needs.
For more information, visit the Company’s website at: www.abattis.com.
ON BEHALF OF THE BOARD
Rene David, Director
For further information, contact the Company at (604) 336-0881 or at firstname.lastname@example.org.
This press release contains forward-looking statements. The use of any of the words “anticipate,” “continue,” “estimate,” “expect,” “may,” “will,” “project,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the expected timing of opening of the Company’s lab, the activities to be undertaken at the lab, the Company’s short and long-term growth plans, the Company’s goal to become one of the premier companies in the cannabis sector, and the Company’s plan to acquire exclusive intellectual property rights to agricultural technologies. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including that the Company will not be able to open its new lab or execute its proposed business plan in the time required or at all due to regulatory, financial or other issues. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where as a result of new information, future events or results, or otherwise, except as required by applicable securities laws.
SOURCE: Abattis Bioceuticals Corp.